Oral, Sublingual, Topical and Vaginal Hormones: Why Route of Administration Matters

Why route of administration matters

The same hormone, at the same total dose, can behave quite differently in the body depending on how it is administered. Route of administration affects how much of a dose reaches systemic circulation, how quickly, in what form, and with what balance of parent hormone to metabolites. This is one of the more consequential and frequently overlooked variables in compounded hormone therapy, which is why Pharmaprodia is publishing it as a dedicated, standalone resource rather than a footnote inside other articles.

Absorption and pharmacokinetics in brief

Pharmacokinetics — how a drug is absorbed, distributed, metabolized and eliminated — is governed substantially by the route it enters the body through. Oral administration requires absorption through the gastrointestinal tract and passage through the liver before reaching systemic circulation. Routes that cross the skin or mucous membranes (sublingual, buccal, topical, vaginal) can reach the bloodstream through different paths, some of which substantially reduce or bypass that hepatic first pass. The practical result is that "same drug, same dose, different route" can mean meaningfully different systemic exposure, time-to-peak concentration, and duration of effect.

First-pass hepatic metabolism

When a substance is absorbed from the gastrointestinal tract, it travels via the portal circulation directly to the liver before reaching the rest of the body. The liver can metabolize a substantial fraction of an orally administered hormone before it ever reaches systemic circulation — this is "first-pass metabolism." The liver is the most recognized site for this, though first-pass metabolism can also occur in the gut wall, lungs, and other metabolically active tissue.^[1] For some hormones (notably oral progesterone, discussed below and in more detail in our progesterone article) first-pass metabolism is not just a loss of potency but a generator of clinically relevant metabolites. For others, first-pass metabolism mainly changes how much total dose is needed orally to achieve a target systemic level. Routes that avoid the GI tract and liver on the way into circulation — sublingual, topical, vaginal — avoid or reduce this effect, for better or worse depending on the hormone and the goal.

Oral administration

Oral dosing is familiar, easy to titrate in small increments, and well studied for many hormone formulations. Its tradeoffs are first-pass hepatic metabolism (reducing bioavailability and, for some hormones, generating specific metabolites) and dependence on consistent GI absorption. Because oral estrogen passes through the liver first, it is understood pharmacologically to have a more direct hepatic effect on liver-synthesized proteins, including certain clotting factors, than non-oral routes do — this is the underlying mechanism.

At the level of observational association, a 2015 systematic review and meta-analysis of 15 studies found oral estrogen therapy associated with an increased risk of a first venous thromboembolism (VTE) event compared with transdermal estrogen (relative risk 1.63; 95% CI, 1.40–1.90), with a similar signal for deep vein thrombosis specifically (RR 2.09; 95% CI, 1.35–3.23), but no statistically significant association with myocardial infarction.^[2]

It matters what kind of evidence this is. All 15 studies in that meta-analysis were observational — none was a randomized controlled trial directly comparing oral and transdermal estrogen for VTE as an outcome — and the review's own authors described their findings as "observational evidence warranting low confidence."^[2] Observational studies of this kind can be affected by confounding: for example, differences in which patients are prescribed oral versus transdermal therapy in the first place, and why. The pharmacologic mechanism, the observational association, and the absence of head-to-head randomized clinical-outcome evidence are three different things, and none of them, alone, is the same as a controlled demonstration that route alone determines an individual patient's cardiovascular or clotting risk — dose, duration, age, personal and family history, and other risk factors are also part of that picture. This is nonetheless one reason route, not just dose, is part of the clinical conversation around estrogen therapy risk.

Sublingual and buccal administration

Placed under the tongue or against the cheek, sublingual and buccal dosing absorb through the oral mucosa directly into systemic circulation, substantially reducing first-pass hepatic metabolism compared with swallowing the same preparation. This route often produces a relatively fast rise to peak concentration and a shorter duration of elevated levels than oral dosing of the same total amount — which has implications both for symptom control patterns throughout the day and for when a blood sample will best reflect "typical" exposure.

Transdermal and topical administration

Topical (transdermal) administration — creams, gels, and patches — delivers hormone through the skin directly into systemic circulation, bypassing first-pass hepatic metabolism entirely. This route is well established for estradiol (transdermal estradiol patches are a standard, FDA-approved option) and is also commonly used in compounded preparations for progesterone and testosterone. Absorption can be affected by application site, skin condition, and individual variability, and topical dosing can be harder to titrate with the same precision as an oral tablet.

Absorption and clinical adequacy are two different questions, and this distinction matters most for transdermal progesterone specifically. Topical progesterone is genuinely absorbed into systemic circulation — it is not a case of "no absorption." However, a 2016 systematic review of the evidence on micronized progesterone and the endometrium found that transdermal micronized progesterone does not provide endometrial protection, in contrast to oral and vaginal micronized progesterone, which the same review found could provide protection at specific studied doses and durations.^[5] This finding is discussed in full, including the specific doses that review examined, in our dedicated progesterone route article.

Vaginal administration

Vaginal administration is used for both localized and systemic effect, depending on the hormone, dose and formulation. For estrogen specifically, low-dose vaginal preparations are generally intended for local genitourinary effect with more limited systemic absorption than oral or transdermal estrogen — the degree of absorption still depends on the specific dose and formulation, and it would be inaccurate to describe any vaginal estrogen product as having no systemic absorption at all.

For vaginal progesterone specifically, pharmacokinetic research has documented a "first-uterine-pass effect": a foundational study found uterine tissue progesterone concentrations more than 10-fold higher after vaginal administration than after systemic (oral) administration, despite plasma progesterone levels being more than seven-fold higher in the systemic-administration group^[3] — indicating a direct vaginal-to-uterine transport pathway distinct from ordinary systemic absorption. This is a tissue-concentration and pharmacokinetic finding, distinct from — though consistent with — clinical evidence that vaginal micronized progesterone, at specific studied doses and durations, can provide endometrial protection.^[5] The specific doses and durations that evidence covers are addressed in more depth in our progesterone route article. Vaginal route pharmacokinetics are genuinely hormone-specific — they should not be generalized from one hormone to another.

This table summarizes general tendencies, not fixed rules — exact pharmacokinetics vary by hormone, specific formulation, dose, and individual patient physiology.

How this differs across progesterone, estrogen and testosterone

Route matters differently for each hormone class:

• Progesterone — oral dosing produces clinically relevant sedative metabolites (allopregnanolone) that other routes largely avoid. Route also directly determines endometrial protection: a systematic review found transdermal micronized progesterone does not provide endometrial protection, while oral and vaginal micronized progesterone can, at specific studied doses^[5] — including via the first-uterine-pass effect for vaginal administration described above.^[3] See our dedicated progesterone route article for detail.
• Estrogen — a systematic review and meta-analysis found oral estrogen associated with higher observational-study risk of venous thromboembolism than transdermal estrogen, though this is observational evidence rather than randomized clinical-trial data (see above).^[2] Low-dose vaginal estrogen is used specifically for local genitourinary effect with more limited (not absent) systemic absorption.
• Testosterone — current clinical practice guidance describes transdermal delivery as "the most physiological form of replacement therapy" and specifically does not recommend oral or intramuscular testosterone formulations, citing adverse effects; topical and sublingual/buccal routes are the most common for compounded testosterone in women.^[4] See our dedicated testosterone article for detail.

Laboratory testing implications by route

Because time-to-peak and duration of elevated levels differ by route, the timing of a blood draw relative to the last dose is one of the most important — and most commonly overlooked — variables in interpreting a hormone level. A trough-timed sample on a sublingual regimen and a random-timed sample on a topical regimen are not directly comparable to each other, or to a single generic reference range built primarily around one route (often oral, historically). Consistent, prescriber-guided timing of testing relative to dosing makes trend data far more useful than an isolated value.

Individualized formulation considerations

Because route changes bioavailability, metabolite profile, and monitoring strategy, choosing a route is not a matter of convenience alone — it is a clinical decision that a prescriber makes based on the specific hormone, the patient's goals and history, tolerability, and how the resulting labs will be interpreted. This individualized, prescriber-directed approach to route and formulation is central to how compounding pharmacies like Pharmaprodia operate, in contrast to a one-size-fits-all commercial product.